RT Journal Article
SR Electronic
T1 Ultrasound to identify lupus patients with inflammatory joint symptoms with a better response to therapy: The USEFUL longitudinal multicentre study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.30.20142687
DO 10.1101/2020.07.30.20142687
A1 Khaled Mahmoud
A1 Ahmed S Zayat
A1 Md Yuzaiful Md Yusof
A1 Katherine Dutton
A1 Lee Suan Teh
A1 Chee-Seng Yee
A1 David D’Cruz
A1 Nora Ng
A1 David Isenberg
A1 Coziana Ciurtin
A1 Philip G Conaghan
A1 Paul Emery
A1 Christopher J Edwards
A1 Elizabeth MA Hensor
A1 Edward M Vital
YR 2020
UL http://medrxiv.org/content/early/2020/07/31/2020.07.30.20142687.abstract
AB Objective To determine whether SLE patients with inflammatory joint symptoms and ultrasound-synovitis achieve better clinical responses to glucocorticoid compared to patients with normal scans. Secondary objectives included identification of clinical features predicting ultrasound-synovitis.Methods A longitudinal muticentre study of SLE patients with physician-diagnosed inflammatory joint pain was undertaken. Clinical assessments, patient-reported outcomes, and bilateral hands and wrist ultrasound were collected at 0-, 2- and 6-weeks after intramuscular methylprednisolone 120mg. The primary outcome (determined via internal pilot analysis) was EMS-VAS at 2-weeks, adjusted for the baseline value, comparing patients with positive (GS≥2 and/or PD≥1) and negative ultrasound. Post-hoc analyses adjusting for fibromyalgia were performed.Results Of 133 patients recruited, 78/133 had positive ultrasound, but only 68% of these had ≥1 swollen joint. Of 66/133 patients with ≥1 swollen joint, 20% had negative ultrasound. Positive ultrasound was associated with joint swelling, symmetrical small joint distribution and serology. In full analysis set (n=133) there was no difference in baseline-adjusted EMS-VAS at week 2 (−7.7mm 95% CI − 19.0mm, 3.5mm, p=0.178). After excluding 32 fibromyalgia patients, response was significantly better in patients with positive ultrasound at baseline (baseline-adjusted EMS-VAS at 2-weeks - 12.1 mm, 95% CI −22.2mm, −0.1mm, p=0.049). This difference was greater when adjusted for treatment (−12.8mm (95% CI −22mm, −3mm), p=0.007). BILAG and SLEDAI responses were higher in ultrasound-positive patients.Conclusions In SLE patients without fibromyalgia, those with positive ultrasound had a better clinical response to therapy. Imaging-detected synovitis should be used to select SLE patients for therapy and enrich clinical trials.Competing Interest StatementDr Vital has received grants from AstraZeneca and Sandoz. He has received honoraria from AstraZeneca, GSK, Roche and Aurinia.Funding StatementThis research was supported by a grant from LupusUK and the National Institute of Health Research (CS-2013-13-032).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West - Greater Manchester Central Research Ethics Committee 16/NW/0060All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact Dr Vital to discuss data availability requests